WEX Inc. (NYSE: WEX), a leading provider of corporate payment
solutions, today announced its wholly owned subsidiary, Evolution1 ,
was named a multiple winner on December 18 in the 2014 Mobile Star
Awards for its 1Mobile
MAA Submission for Migalastat Monotherapy for Fabry Disease on Track for Mid-2015 Next-Generation Pompe ERT Set to Enter Clinic in 2H15 FY15 Cash Spend Guidance of $73-$83 Million — Current Cash Expected to Fund Operations into 2017
CRANBURY, N.J., Jan.
Lululemon Athletica's stock (LULU) rallied 4% in premarket trade Monday, after the yoga apparel maker raised its profit and sales outlook for the fiscal fourth quarter on the heels of strong holiday results.
Opus Bank (“Opus” or the “Bank”) (NASDAQ: OPB) announced today that Dan
Borland, Executive Vice President, President of Commercial Real Estate
Banking, has been named a member of Opus’ Executive Committee.
Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today will report on the ongoing execution of its multi-year, strategic
initiative to sharpen its commercial and research and development (R&D)
focus, redesign its operating model and reduce its cost base.
New York & Company, Inc. (NYSE:NWY), a specialty apparel chain with 512
retail stores, today commented on its holiday performance and fourth
quarter fiscal year 2014 outlook ahead of its presentation at the ICR
Acceleron Pharma Inc. (NASDAQ:XLRN), a biopharmaceutical company focused
on the discovery, development and commercialization of novel protein
therapeutics for cancer and rare diseases, today announced its major
corporate research and development objectives for 2015.
Demandware® Inc. (NYSE:DWRE)
the industry-leading provider of enterprise cloud commerce solutions,
today announced that it has agreed to acquire Tomax, an enterprise cloud
software company that provides an integrated solution for retail
point-of-sale (POS) and store operations.
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a developer of innovative
RNA-based therapeutics, today announced data through Week 168 from Study
202, a Phase IIb open-label extension study of eteplirsen in patients
with Duchenne muscular dystrophy (DMD). After more than three years of
treatment, results of the 6-minute walk test (6MWT) at 168 weeks showed
continued ambulation across all patients evaluable on the test, however
all patients showed a decline in distance walked on this measure since
the week 144 timepoint.
Independent. Insightful. Trusted. Morningstar provides stock market analysis; equity, mutual fund, and ETF research, ratings, and picks; portfolio tools; and option, hedge fund, IRA, 401k, and 529 plan research. Our reliable data and analysis can help both experienced enthusiasts and newcomers.